tiprankstipranks
Trending News
More News >

Kissei Pharmaceutical Advances with Linzagolix for Uterine Fibroids

Story Highlights
  • Kissei Pharmaceutical focuses on developing drugs for uterine fibroids and endometriosis.
  • Kissei submitted a new drug application in Japan for Linzagolix, showing promising trial results.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Kissei Pharmaceutical Advances with Linzagolix for Uterine Fibroids

Confident Investing Starts Here:

The latest update is out from Kissei Pharmaceutical Co ( (JP:4547) ).

Kissei Pharmaceutical Co., Ltd. has submitted a new drug application in Japan for Linzagolix, a GnRH antagonist aimed at treating uterine fibroids. The drug has shown promising results in clinical trials and is already being launched in Europe by licensee Theramex. This development is part of Kissei’s broader strategy to expand its market presence and provide effective treatments for women’s health issues globally.

More about Kissei Pharmaceutical Co

Kissei Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and marketing of drugs. The company is headquartered in Matsumoto, Nagano, Japan, and is involved in the creation of treatments for conditions such as uterine fibroids and endometriosis.

YTD Price Performance: -9.27%

Average Trading Volume: 750

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $1.01B

See more data about 4547 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App